Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.57 |
| ▸ | SMO | Q99835 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791511 | 0.98 | HTT (0.57) | HTTLMNAALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6798643 | 0.93 | ALDH1A1 (0.58) | HTTLMNAALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6789227 | 0.92 | LMNA (0.50) | HTTLMNAALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6792583 | 0.92 | KMT2A (0.56) | HTTLMNAALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6794915 | 0.91 | LMNA (0.49) | HTTLMNAALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6793707 | 0.91 | CNR1 (0.58) | HTTLMNAALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6793890 | 0.91 | RAB9A (0.54) | HTTLMNAALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6794391 | 0.91 | HTT (0.49) | HTTLMNAALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6788981 | 0.91 | HTT (0.49) | HTTLMNAALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6787263 | 0.91 | HTT (0.49) | HTTLMNAALDH1A1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090069310-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-03-12 | — | — | US | disclosed |
| US-20080187978-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-08-07 | — | — | US | disclosed |
| US-20080064688-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-03-13 | — | — | US | disclosed |
| US-20080045531-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045531-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-02-21 | — | — | US | disclosed |
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064688-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HTT 3954/4885LMNA 3791/4885ALDH1A1 3257/4885 |
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HTT 3954/4885LMNA 3791/4885ALDH1A1 3257/4885 |
| US-20090069310-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HTT 3954/4885LMNA 3791/4885ALDH1A1 3257/4885 |
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | HTT 3988/4885LMNA 3620/4885ALDH1A1 3608/4885 |
| US-20080045531-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HTT 3954/4885LMNA 3791/4885ALDH1A1 3257/4885 |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | HTT 2566/4885LMNA 1239/4885ALDH1A1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.